Go to http://www.dpbolvw.net/click-2444502-7201467 Go to http://www.kqzyfj.com/click-2444502-5338696 Go to http://www.kqzyfj.com/click-2444502-10457547 Go to http://www.tkqlhce.com/click-2444502-10296014
Your Ad Here

Tysabri® Demonstrates Significant Health-Related Quality Of Life Improvements For Multiple Sclerosis Patients

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today the publication of results demonstrating that patients treated with TYSABRI® (natalizumab) showed a significant improvement in health-related quality of life (HRQoL) measures when compared to placebo. These results are from the first Phase III multiple sclerosis (MS) studies that have demonstrated improvement on HRQoL measures in patients with relapsing forms of MS.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • Furl
  • Simpy
  • Spurl
  • Technorati
Read the full article...
Posted in Multiple Sclerosis on Aug 26th, 2007, 2:00 am     

NICE Recommends Tysabri For Use In Highly Active Relapsing Remitting Multiple Sclerosis

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) welcome final guidance announced by the National Institute for Health and Clinical Excellence (NICE) recommending use of TYSABRI (natalizumab) in people with highly active relapsing remitting multiple sclerosis (RRMS). TYSABRI is the first treatment for multiple sclerosis to be recommended for use by NICE.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • Furl
  • Simpy
  • Spurl
  • Technorati
Read the full article...
Posted in Multiple Sclerosis on Aug 24th, 2007, 3:00 am     

Results Published On BHT-3009, Experimental DNA Vaccine Treatment For MS

An early-phase study of BHT-3009 (Bayhill Therapeutics), both alone and in combination with Lipitor® (atorvastatin, Pfizer, Inc.) found the drug to be safe and to induce a beneficial immune response in relapsing-remitting+ or secondary-progressive MS**. BHT-3009 is a vaccine containing genetic material that instructs cells to produce myelin basic protein (MBP), a component of myelin, an immune target in MS.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • Furl
  • Simpy
  • Spurl
  • Technorati
Read the full article...
Posted in Multiple Sclerosis on Aug 19th, 2007, 3:00 am     

Italian-German Research Team Discovers Cellular Marker For Multiple Sclerosis

In their search for the cellular and molecular causes of multiple sclerosis, an Italian-German research team has identified a subgroup of protective immune cells (suppressor cells) which are strikingly reduced in number in patients with this nervous system disorder. These suppressor cells are characterized by a specific surface marker, called CD39, and degrade ATP, an energy carrier released from damaged tissues.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • Furl
  • Simpy
  • Spurl
  • Technorati
Read the full article...
Posted in Multiple Sclerosis on Aug 17th, 2007, 3:00 am     

« Previous Page

 
Go to http://www.jdoqocy.com/click-2444502-10378034 Go to http://www.anrdoezrs.net/94116lnwtnvADFFFGBDACBGBHKIC Go to http://www.tkqlhce.com/click-2444502-10426254 Go to http://www.anrdoezrs.net/94116lnwtnvADFFFGBDACBGBHKIC